2 completed, 1 not yet recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Ding-Wei Ye: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT - Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer) | Phase 3 | Not yet recruiting | Ding-Wei Ye | 400 | 2025-01-30 | 2025-01-10 |
| Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study Renal Cell Carcinoma (RCC) | Completed | Ding-Wei Ye | 232 | 2024-06-01 | 2025-03-19 | |
| A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer VG161 via Intravesical Instillation - NMIBC | Phase 1 / Phase 2 | Completed | Ding-Wei Ye | 20 | 2021-10-12 | 2026-04-01 |
Carcinoma, Renal Cell (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Abiraterone Acetate (1) · Androgen Antagonists (1) · BID protein, human (1) · Prednisolone (1)
China (3)